GlassScriptPhysician profile
Alyssa N Grubb
NPI 1588148738
$11,329.58
in general payments reported to CMS, 2019-2025
37 companies · $2,534 in 2025
The $2,534 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,910 · 2022: $2,284 · 2023: $2,067 · 2024: $2,535 · 2025: $2,534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,135.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,660.79 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,083.61 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $914.23 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Qol Medical, LLC | $698.94 | 2021-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $631.92 | 2021-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $576.36 | 2021-2025 | |
| Celgene Corporation | $533.40 | 2021-2023 | Zeposia |
| Ardelyx, INC. | $528.79 | 2024-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $409.45 | 2021-2024 | Dificid |
| Madrigal Pharmaceuticals | $355.31 | 2024-2025 | Rezdiffra, Resmetirom |
| Redhill Biopharma INC. | $342.00 | 2021-2024 | Talicia, Aemcolo |
| Pfizer INC. | $330.44 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $223.04 | 2021-2023 | |
| Vivus LLC | $217.33 | 2021-2025 | Pancreaze, Qsymia |
| Ironwood Pharmaceuticals, INC | $199.33 | 2022-2025 | Linzess |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $184.51 | 2022-2025 | Ocaliva |
| Genzyme Corporation | $174.90 | 2022-2024 | |
| Braintree Laboratories, INC. | $159.95 | 2021-2023 | Suflave, Sutab |
| Phathom Pharmaceuticals, INC. | $139.79 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $115.78 | 2024-2025 | Zenpep |
| Ferring Pharmaceuticals INC. | $102.87 | 2021-2025 | Rebyota, Clenpiq |
| Alnylam Pharmaceuticals INC. | $78.14 | 2024-2025 | Givlaari |
| Janssen Scientific Affairs, LLC | $70.21 | 2023 | Stelara |
| Ucb, INC. | $67.00 | 2021 | |
| Boston Scientific Corporation | $65.70 | 2022-2023 | Watchman Flx |
| Lilly USA, LLC | $63.67 | 2024-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $57.98 | 2025 | Iqirvo |
| Celltrion USA INC. | $50.27 | 2024 | Vegzelma |
| Organon LLC | $48.91 | 2021-2023 | Hadlima |
| Csl Behring | $43.87 | 2022 | |
| Novo Nordisk INC | $43.04 | 2025 | Wegovy |
| Amgen INC. | $41.43 | 2022-2023 | Avsola |
| Evoke Pharma, INC. | $39.63 | 2023-2025 | Gimoti |
| Fresenius Kabi USA, LLC | $30.22 | 2024 | Idacio |
| Regeneron Healthcare Solutions, INC. | $17.47 | 2022 | |
| Ethicon US, LLC | $17.36 | 2022 | |
| Horizon Therapeutics Plc | $11.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Grubb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.